Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cirrocure-DS is a hepatoprotective pharmaceutical product marketed by Symbiosis Labs, an Indian generic pharmaceutical company. While specific pharmacological details are not provided on the manufacturer's website, the nomenclature strongly suggests a formulation intended for the management of liver-related conditions, such as cirrhosis or fatty liver disease, with the 'DS' suffix typically denoting a 'Double Strength' formulation. In the context of the Indian pharmaceutical market, products with similar branding often contain hepatoprotective agents such as silymarin, ursodeoxycholic acid, or L-ornithine L-aspartate, or they may be polyherbal Ayurvedic formulations intended to support liver function and regeneration. As a product of Symbiosis Labs, it is positioned as a commercially available generic or proprietary blend rather than an investigational new drug in clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cirrocure-DS.